cassava
sciences
phase
clinical
results
alzheimer
selected
news
ctad
austin
texas
globe
newswire
cassava
sciences
nasdaq
sava
biopharmaceutical
company
focused
alzheimer
disease
today
announced
clinical
results
phase
study
sumifilam
selected
oral
presentation
international
conference
clinical
trials
alzheimer
disease
ctad
ctad
prestigious
annual
conference
focused
alzheimer
research
development
takes
place
year
virtual
event
november
members
ctad
scientific
committee
select
research
abstracts
oral
presentation
based
medical
scientific
significance
quality
data
methodology
details
presentation
title
sumifilam
significantly
improves
eleven
csf
biomarkers
randomized
clinical
trial
alzheimer
disease
presentation
type
oral
presentation
presenter
lindsay
burns
phd
svp
neuroscience
cassava
sciences
date
time
november
est
venue
virtual
conference
cassava
sciences
ctad
presentation
made
available
day
presentation
corporate
website
investors
page
cassava
sciences
recently
announced
final
results
phase
study
sumifilam
lead
drug
candidate
alzheimer
disease
clinical
study
funded
national
institutes
health
nih
alzheimer
patients
treated
mg
mg
sumifilam
days
showed
statistically
significant
p
improvements
biomarkers
disease
pathology
neurodegeneration
neuroinflammation
versus
alzheimer
patients
took
placebo
addition
alzheimer
patients
treated
sumifilam
showed
improvements
validated
tests
episodic
memory
spatial
working
memory
versus
patients
placebo
effect
size
cognitive
improvements
correlated
strongly
decreases
levels
phase
study
conclusions
small
study
sumifilam
showed
promising
treatment
effects
patients
alzheimer
disease
study
sumifilam
treatment
days
improved
entire
panel
validated
biomarkers
alzheimer
disease
decreased
measurements
neuroinflammation
showed
responder
rate
safe
appears
benefit
cognition
importantly
data
consistent
prior
clinical
preclinical
results
drug
mechanism
action
years
basic
research
ongoing
study
cassava
sciences
currently
conducting
study
sumifilam
mg
months
study
target
enrollment
approximately
patients
alzheimer
disease
study
enrolled
alzheimer
disease
alzheimer
disease
progressive
brain
disorder
destroys
memory
thinking
skills
currently
drug
therapies
halt
alzheimer
disease
much
less
reverse
course
alone
approximately
million
people
currently
living
alzheimer
disease
approximately
people
age
older
developed
alzheimer
number
people
living
alzheimer
disease
expected
grow
dramatically
years
ahead
resulting
growing
social
economic
sumifilam
sumifilam
proprietary
small
molecule
oral
drug
restores
normal
shape
function
altered
filamin
flna
scaffolding
protein
brain
altered
flna
brain
disrupts
normal
function
neurons
leading
alzheimer
pathology
neurodegeneration
neuroinflammation
underlying
science
sumifilam
published
journals
including
journal
neuroscience
neurobiology
aging
journal
biological
chemistry
neuroimmunology
neuroinflammation
journal
prevention
alzheimer
disease
company
also
developing
investigational
diagnostic
called
savadx
detect
alzheimer
disease
simple
blood
test
sumifilam
savadx
developed
product
candidates
substantially
funded
research
grant
awards
national
institutes
health
cassava
sciences
owns
worldwide
development
commercial
rights
research
programs
alzheimer
disease
related
technologies
without
royalty
obligations
third
party
patent
protection
area
currently
runs
beyond
plus
extensions
includes
seven
issued
patents
related
patent
filings
applications
cassava
sciences
cassava
sciences
mission
discover
develop
innovations
chronic
neurodegenerative
conditions
past
years
cassava
sciences
combined
technology
new
insights
neurobiology
develop
novel
solutions
alzheimer
disease
information
please
visit
https
information
please
contact
eric
schoen
chief
financial
officer
eschoen
cassava
sciences
phase
study
sumifilam
alzheimer
disease
funded
clinical
research
grant
national
institutes
health
nih
nia
content
press
release
solely
responsibility
cassava
sciences
necessarily
represent
official
views
nih
nia
cautionary
note
regarding
statements
press
release
contains
statements
purposes
private
securities
litigation
reform
act
act
cassava
sciences
claims
protection
safe
harbor
statements
contained
act
statements
statements
historical
fact
contained
press
release
including
limited
statements
regarding
status
current
future
clinical
studies
sumifilam
interpretation
results
phase
clinical
studies
including
cognition
data
plans
discuss
clinical
results
ctad
potential
health
benefits
changes
levels
biomarkers
verbal
commentaries
made
cassava
sciences
employees
scientific
advisors
potential
benefits
company
product
candidates
alzheimer
disease
statements
statements
based
largely
company
current
expectations
projections
future
events
statements
speak
date
press
release
subject
number
risks
uncertainties
assumptions
including
limited
risks
relating
ability
conduct
complete
clinical
studies
expected
timelines
demonstrate
specificity
safety
efficacy
potential
health
benefits
product
candidates
severity
duration
health
care
precautions
given
pandemic
unanticipated
impacts
pandemic
business
operations
including
described
section
entitled
risk
factors
cassava
sciences
annual
report
form
year
ended
december
future
reports
filed
sec
light
risks
uncertainties
assumptions
statements
events
discussed
press
release
inherently
uncertain
may
occur
actual
results
could
differ
materially
adversely
anticipated
implied
statements
accordingly
rely
upon
statements
predictions
future
events
except
required
law
company
disclaims
intention
responsibility
updating
revising
statements
contained
press
release
information
regarding
risks
related
business
investors
consult
filings
sec
available
sec
website
source
alzheimer
association
alzheimer
disease
facts
figures
available
online
https
media
documents
